share_log

424B3: Prospectus

424B3: Prospectus

424B3：募资说明书
美股SEC公告 ·  09/10 19:28

Moomoo AI 已提取核心信息

ZyVersa Therapeutics, a clinical-stage biopharmaceutical company, has announced a prospectus for the potential offering of up to $100 million in mixed securities, which may include common stock, preferred stock, debt securities, warrants, purchase contracts, units, and subscription rights. The securities may be offered in various combinations and in one or more offerings. The securities may be convertible, exercisable, or exchangeable for other securities, and the offerings may be conducted through underwriters, dealers, agents, or directly to purchasers. The company has conducted reverse-stock-splits on December 4, 2023, and April 25, 2024, with ratios of 1-for-35 and 1-for-10, respectively, and all share and price information has been adjusted accordingly. The company's common stock is listed on The Nasdaq Stock Market LLC under the...Show More
ZyVersa Therapeutics, a clinical-stage biopharmaceutical company, has announced a prospectus for the potential offering of up to $100 million in mixed securities, which may include common stock, preferred stock, debt securities, warrants, purchase contracts, units, and subscription rights. The securities may be offered in various combinations and in one or more offerings. The securities may be convertible, exercisable, or exchangeable for other securities, and the offerings may be conducted through underwriters, dealers, agents, or directly to purchasers. The company has conducted reverse-stock-splits on December 4, 2023, and April 25, 2024, with ratios of 1-for-35 and 1-for-10, respectively, and all share and price information has been adjusted accordingly. The company's common stock is listed on The Nasdaq Stock Market LLC under the symbol 'ZVSA.' As of August 30, 2024, the last reported sale price of ZyVersa's common stock was $2.77 per share. The company has not offered any securities pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to and including the date of this prospectus. The date of the prospectus is September 9, 2024.
ZyVersa Therapeutics，一家临床阶段的生物制药公司，已宣布拟发行高达10000亿美元的混合证券的招股说明书，其中可能包括普通股、优先股、债务证券、认股权证、购买合同、单位和认购权。这些证券可以以各种组合方式和一个或多个发行方式进行发行。这些证券可能可以转换、行使或交换其他证券，发行可以通过承销商、经销商、代理商或直接向购买者进行。公司在2023年12月4日和2024年4月25日进行了股票的反拆分，比率分别为1比35和1比10，所以所有的股票和价格信息都经过了相应调整。公司的普通股在纳斯达克证券交易所的股票代码为'ZVSA'。截至2024年8月30日，ZyVersa的普通股最近的成交价格为每股2.77美元。在本招股说明书发行日之前12个日历月内，公司尚未根据S-3表格的I.b.6通用说明发行任何证券。招股说明书的日期是2024年9月9日。
ZyVersa Therapeutics，一家临床阶段的生物制药公司，已宣布拟发行高达10000亿美元的混合证券的招股说明书，其中可能包括普通股、优先股、债务证券、认股权证、购买合同、单位和认购权。这些证券可以以各种组合方式和一个或多个发行方式进行发行。这些证券可能可以转换、行使或交换其他证券，发行可以通过承销商、经销商、代理商或直接向购买者进行。公司在2023年12月4日和2024年4月25日进行了股票的反拆分，比率分别为1比35和1比10，所以所有的股票和价格信息都经过了相应调整。公司的普通股在纳斯达克证券交易所的股票代码为'ZVSA'。截至2024年8月30日，ZyVersa的普通股最近的成交价格为每股2.77美元。在本招股说明书发行日之前12个日历月内，公司尚未根据S-3表格的I.b.6通用说明发行任何证券。招股说明书的日期是2024年9月9日。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间